Stock PLRX PLIANT THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Real-time Estimate Cboe BZX
Other stock markets
 01:46:55 2024-05-23 pm EDT 		5-day change 1st Jan Change
13.68 USD -3.56% Intraday chart for Pliant Therapeutics, Inc. -10.83% -23.14%
May. 14 Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading MT
May. 14 Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
GL
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading
MT
Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial
MT
Pliant Therapeutics : Phase 2a PET Imaging Trial
PU
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
GL
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
AQ
Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
CI
Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating
MT
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
GL
RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk
MT
Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GL
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Pliant Therapeutics to Participate in Upcoming Investor Events
GL
Pliant Therapeutics to Participate in Upcoming Investor Events
AQ
Pliant Therapeutics to Participate in Upcoming Investor Events
GL
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
GL
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
AQ
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
CI
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PLRX Stock
  4. News Pliant Therapeutics, Inc.